Ucb Biopharma Srl
Clinical trials sponsored by Ucb Biopharma Srl, explained in plain language.
Belgian biopharmaceutical company focused on neurology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Parkinson's drug trial halted: what we learned from UCB0599
Disease control TerminatedThis study looked at whether taking UCB0599 early or later could slow brain changes in people with Parkinson's disease. It involved 428 adults who had already completed an earlier study. The trial was stopped early, but researchers measured brain scans and medication use over 18 …
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug tested for newborn seizures – but trial halted early
Disease control TerminatedThis study tested the drug lacosamide in newborns with repeated seizures that were not controlled by standard medicines. The trial was small (29 babies) and was stopped early. Researchers compared lacosamide to usual care to see if it could reduce seizure time on brain monitoring…
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Early safety check for new drug UCB3101 in healthy volunteers
Knowledge-focused TerminatedThis study was an early, first-in-human trial to see if a single dose of UCB3101 is safe and tolerable in healthy adults aged 18 to 65. Researchers gave either the drug or a placebo and watched for side effects. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC